MS
Morgan Stanley
MS has lower modeled downside risk, despite its lower overall score.
PRAA
PRA Group, Inc.
PRAA has a slight edge over MS overall, supported by stronger valuation.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
PRAA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
PRAA's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like PRAA.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
PRAA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 2.9x | $11.88 | — |
| Forward | 6.5x | $11.88 | — |
| Cheap | 9.6x | $39.16 | +230% |
| Fair | 11x | $47.03 | +296% |
| Expensive | 20x | $83.73 | +605% |
Historical ranges are pointers, not guarantees.
PRAA has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over PRAA on the outlook, with more favorable valuation and earnings expectations.
PRAA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect PRAA's earnings, revenue and profitability to hold roughly steady.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over PRAA on earnings, with more consistent year-over-year improvement.
PRAA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.82 | -55% |
| Q3 2026 | $4.10 | +$12.89 |
| Q2 2026 | -$6.72 | -388% |
| Q1 2026 | -$7.15 | -499% |
| Q4 2025 | -$7.79 | -535% |
| Q3 2025 | -$8.79 | -899% |
| Q2 2025 | $2.33 | +2230% |
| Q1 2025 | $1.79 | +$2.33 |
| Q4 2024 | $1.79 | +$3.92 |
PRAA has returned to profit: it earned $4.10 per share over the past year, after losing money the year before.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over PRAA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over PRAA on profitability, with a higher operating margin.
PRAA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $286.3M | -8% |
| Q2 2026 | $372.2M | +29% |
| Q1 2026 | $314.5M | +17% |
| Q4 2025 | $333.4M | +14% |
| Q3 2025 | $311.1M | +11% |
| Q2 2025 | $287.7M | +1.2% |
| Q1 2025 | $269.6M | +5.5% |
| Q4 2024 | $293.2M | +32% |
PRAA's revenue is growing: $286M last quarter, down 8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +131 points |
| Q2 2026 | 41% | +12 points |
| Q1 2026 | 33% | +5.2 points |
| Q4 2025 | 38% | +5.6 points |
| Q3 2025 | -101% | -133 points |
| Q2 2025 | 30% | -1.8 points |
| Q1 2025 | 28% | +1.7 points |
| Q4 2024 | 32% | +12 points |
PRAA's operating margin was 30% last quarter, up 131 points from the same quarter a year ago.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
PRAA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.7M | -$11.3M |
| Q2 2026 | -$38.7M | -$24.5M |
| Q1 2026 | $23.5M | +$77M |
| Q4 2025 | -$11.3M | -127% |
| Q3 2025 | -$11.3M | +$24.7M |
| Q2 2025 | -$14.2M | +$16.6M |
| Q1 2025 | -$53.5M | +$20M |
| Q4 2024 | $41.8M | +107% |
PRAA has the edge over MS on cash flow, with more consistent year-over-year improvement.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has 1.6B diluted shares, down 1.5% from a year ago.
PRAA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -282K shares |
| 1 year | -2.7% | -1.1M shares |
| 3 years | -3.1% | -1.2M shares |
| 5 years | -17% | -7.6M shares |
| Available history | -17% | -7.6M shares |
PRAA has the edge over MS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $10M |
| Q1 2026 | $10M |
| Q4 2025 | $10M |
| Q3 2025 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q1 2023 | — |
PRAA spent $30M buying back its own shares over the past year.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
PRAA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | -0.5x | Net Cash |
| Q1 2024 | -0.5x | Net Cash |
| Q4 2023 | -1.0x | Net Cash |
| Q3 2023 | -0.8x | Net Cash |
PRAA has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like PRAA.
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
PRAA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 21.1 | Neutral |
PRAA's weekly RSI is 33 (neutral) and its Stochastic is 21 (neutral).
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
PRAA PE vs Financial Services Sector
| Metric | PRAA | Sector median | Relative |
|---|---|---|---|
| PE | 2.9x | 13x | 78% below |
| PE % | 0 | 63 | 63 pts below |
PRAA has the edge over MS on valuation relative to its sector.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS has the edge over PRAA on trend strength, trading above more of its moving averages.
PRAA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.8 | 33% below |
| 20 week MA | $18.5 | 36% below |
| 50 week MA | $17.4 | 32% below |
| 100 week MA | $17.4 | 32% below |
| 200 week MA | $21.0 | 43% below |
PRAA is in a downtrend: it's below all five of its weekly moving averages, and 43% below its 200-week average.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over PRAA on returns for 2026, with the stronger performance.
PRAA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.5 | $38.8 | +6.2% |
| 2021 | $38.8 | $48.5 | +25% |
| 2022 | $48.5 | $33.4 | -31% |
| 2023 | $33.4 | $26.2 | -22% |
| 2024 | $26.2 | $20.5 | -22% |
| 2025 | $20.5 | $17.6 | -14% |
| 2026 YTD | $17.6 | $11.9 | -33% |
PRAA has finished four years in a row lower, and it's down 33% so far in 2026.